This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment

7.5.1 Case Study - Mankind, Sales Excellence 71

7.6 Patented Products Introduced in Niche Segments 72

7.6.1 Case Study - Merck's Successful Strategy for Patented Products 72

7.7 Actions Taken by Indian Government against Counterfeit Drugs 73

8 Indian Pharmaceutical Market Outlook – Competitive Landscape 74

8.1 Key Foreign Companies 74

8.1.1 Sanofi 74

8.1.2 Roche 74

8.1.3 AstraZeneca 75

8.1.4 GlaxoSmithKline 75

8.1.5 Abbott Laboratories 75

8.2 Key Domestic Companies 76

8.2.1 Dr. Reddy's Laboratories 76

8.2.2 Lupin 78

8.2.3 Cipla Limited 80

8.2.4 Ranbaxy Laboratories Limited 81

8.2.5 Biocon 83

9 Indian Pharmaceutical Market Outlook – The Way Forward 85

9.1 Outlook for the Indian Pharmaceutical Industry 85

9.2 Risks 86

9.2.1 Currency Fluctuation and Financial Problems will make it Difficult to Sustain Growth 86

9.2.2 Regulatory Hurdles 86

9.2.3 Financial Disparity 86

9.2.4 Intellectual Property Concerns 86

9.3 Recommendations 87

9.3.1 Improved Links between Industry and Academia 87

9.3.2 Focus on R&D Initiatives and Skilled Manpower 87

9.3.3 Support for Clinical Trials Sector 87

9.3.4 Quality Drugs to be made Affordable and Accessible 87

9.4 Opportunities Ahead 88

9.5 Strategies for Future Success 88

9.5.1 Increasing Importance of Biosimilars 88

9.5.2 Rural Markets 89

10 Indian Pharmaceutical Market Outlook – Appendix 90

10.1 Market Definitions 90

10.2 Abbreviations 90

10.3 Bibliography 92

10.4 Research Methodology 93

10.4.1 Coverage 93

10.4.2 Secondary Research 93

10.4.3 Primary Research 93

10.4.4 Expert Panel Validation 94

10.5 Contact Us 94

10.6 Disclaimer 94

 

 

 

List of Tables

 

Table 1: Pharmaceutical Market, India, Share of Pharmaceutical Products in Total Exports and Imports (%), 2012 12

Table 2: Pharmaceutical Market, India, Population by Age Group (%), 2001–2026 13

Table 3: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981–2009 15

Table 4: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980–1998 16

Table 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1999–2009 16

Table 6: Pharmaceutical Market, India, Ceiling Price Reduction and Impact, 2012 31

Table 7: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012 35

Table 8: Pharmaceutical Market, India, Indian Biosimilar Companies with Marketed Products in India, 2010 40

Table 9: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007–2011 44

Table 10: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007–2011 45

Table 11: Pharmaceutical Market, India, Anti-Infectives Market Revenue, ($bn), 2005–2010 47

Table 12: Pharmaceutical Market, India, Anti-Infectives, Major Companies and Brands, 2011 48

Table 13: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005–2010 49

Table 14: Pharmaceutical Market, India, Gastrointestinal Market Revenue, ($m), 2005–2010 51

Table 15: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005–2010 53

Table 16: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005–2010 55

Table 17: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005–2010 57

Table 18: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005–2010 59

Table 19: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005–2010 61

Table 20: Pharmaceutical Market, India, Dr. Reddy's Laboratories, Strategic Consolidations, 2011–2012 77

Table 21: Pharmaceutical Market, India, Lupin, Strategic Consolidations, 2011 79

Table 22: Pharmaceutical Market, India, Cipla, Strategic Consolidations, 2012 80

Table 23: Pharmaceutical Market, India, Ranbaxy, Strategic Consolidations, 2011–2012 82

Table 24: Pharmaceutical Market, India, Biocon, Strategic Consolidations, 2011–2012 84

 

5 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs